|
Post by mssciguy on Nov 14, 2015 10:57:05 GMT -5
Novo is very smart. They would make a great partner. They've been recruiting in Lilly's backyard for years, now they are even opening up a peptide lab in Lilly's backyard too, using local talent including a half dozen university MD PhDs ... (disclaimer: rumor)..... But they have a competing meal time insulin which SNY doesn't have ... Apidra market share is negligible... So SNY should have every reason to push Afrezza How much patent life left for Novo's prandial?
|
|